New hope for lung cancer patients Who've tried everything?

NCT ID NCT06879717

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This trial tests a new drug called roginolisib combined with two other drugs (dostarlimab and docetaxel) in 45 adults with advanced non-squamous lung cancer that has worsened after standard treatments. The main goals are to see if the combo is safe and whether it reduces certain immune cells in the blood. It is an early-stage study, so the focus is on safety and immune response rather than cure.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
roginolisib (tablet), dostarlimab (IV infusion), docetaxel (IV infusion)
What this could lead to
If successful, this could offer a new treatment option for people with advanced lung cancer who have run out of standard therapies.
What could go wrong
This is an early-phase trial with only 45 participants, so results may not apply to everyone. The combination may cause significant side effects or fail to shrink tumors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED NON SQUAMOUS NSCLC are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • AZ Delta VZW

    Roeselare, 8800, Belgium

  • Antwerp University Hospital

    Antwerp, 2650, Belgium

  • Hospital Universitari Son Espases

    Palma, 07120, Spain

  • Hospital Universitario y Politécnico La Fe

    Valencia, 46026, Spain

  • Humanitas University, Department of Medical Oncology

    Rozzano, Milan, 20072, Italy

  • Institut Català d'Oncologia Hospitalet

    Barcelona, 08908, Spain

  • Istituto Romagnolo per lo studio dei Tumori "Dino Amadori"

    Meldola, Forlì-Cesena, 47014, Italy